Skip to content
HowShorted

Oruka Therapeutics, Inc. short interest in 2022

In 2022, Oruka Therapeutics, Inc.'s disclosed short interest ran from 2.26% of shares outstanding on 14 Jan 2022 to 0.36% on 15 Dec 2022, a change of -1.90 percentage points. The year's high was 2.26% on 14 Jan 2022 and its low 0.35% on 31 Oct 2022, averaging 1.04% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.39 days on 15 Feb 2022. Full history: Oruka Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Oruka Therapeutics, Inc. in 2022

2022 in figures

Start of year
2.26% (14 Jan 2022)
End of year
0.36% (15 Dec 2022)
Change
-1.90 pp
High
2.26% (14 Jan 2022)
Low
0.35% (31 Oct 2022)
Average
1.04%
Highest days to cover
4.39 (15 Feb 2022)
SEC filings marked
8

Every report in 2022

Oruka Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20222.26%1.83
31 Jan 20222.23%2.46
15 Feb 20222.09%4.39
28 Feb 20221.92%2.57
15 Mar 20221.62%1.8710-K filed, results (8-K)
31 Mar 20221.97%1.13
14 Apr 20221.60%1.00
29 Apr 20221.53%1.67
13 May 20221.41%2.0210-Q filed, results (8-K)
31 May 20221.16%2.93
15 Jun 20220.99%4.06
30 Jun 20220.73%1.82
15 Jul 20220.50%1.87
29 Jul 20220.40%1.58
15 Aug 20220.39%1.6410-Q filed, results (8-K)
31 Aug 20220.37%1.67
15 Sep 20220.55%1.97
30 Sep 20220.40%1.38
14 Oct 20220.39%2.89
31 Oct 20220.35%2.3610-Q filed, results (8-K)
15 Nov 20220.35%2.27
30 Nov 20220.37%2.65
15 Dec 20220.36%1.71

See also: Oruka Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.